Vitestro announced that it has raised $22 million (€20 million) in funding to accelerate commercialization of its robotic blood drawing device. This brings its total funding raised to $50 million (€46 million) from both equity investments and grant funding.
Co-led by return investor Sonder Capital and new investor NYBC Ventures, with participation from Invest-NL, the European Innovation Council Fund (EIC Fund), and existing private investors, the oversubscribed funding round will support Vitestro’s commercialization in Europe and its organizational expansion into the U.S. market.
Through a combination of artificial intelligence (AI), advanced imaging technology, and robotics, Vitestro enables hospitals and labs to provide autonomous blood draws, reducing the need for manual handling and improving patient and clinician satisfaction.
Multiple Vitestro devices have already been pre-ordered and are scheduled to be deployed at several European hospitals starting at the end of this year to help ease workload and provide a more consistent, improved patient experience. Vitestro is also currently leading the A.D.O.P.T. trial, the world’s largest evaluation of autonomous blood drawing devices.
Vitestro plans to use the most recent funding to expand the team to meet the growing demand for its innovative robotic blood drawing device and develop additional product features. Vitestro is on track to obtain CE approval for its device by the end of 2024, with deployment efforts expected to begin in that same timeframe.
